Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Halozyme Therapeutics
Pharma
FDA approves J&J's new challenge to Tagrisso
Subcutaneous Rybrevant will be a better tool for J&J in its uphill fight against AstraZeneca’s Tagrisso in EGFR-mutated lung cancer.
Angus Liu
Dec 18, 2025 10:40am
Halozyme CEO targets new deals as IRA uncertainty subsides
Oct 14, 2025 9:40am
Enhertu, Akeso, Fujifilm-Regeneron—Fierce Pharma Asia
Apr 25, 2025 8:45am
Halozyme sues Merck over subcutaneous Keytruda
Apr 24, 2025 2:41pm
FDA approves BMS' subcutaneous Opdivo with some limitations
Jan 2, 2025 9:15am
Argenx adds 4 new targets to Halozyme collab for $30M
Oct 3, 2024 10:54am
